Literature DB >> 32502647

The role of AMPKα2 in the HFD-induced nonalcoholic steatohepatitis.

Xuejiao Zhang1, Sasa Liu1, Chang Zhang2, Shitian Zhang1, Yingying Yue1, Youyi Zhang3, Liming Chen1, Zhi Yao1, Wenyan Niu4.   

Abstract

Nonalcoholic fatty liver disease (NAFLD) is associated with hepatic steatosis, inflammation and liver fibrosis and has become one of the leading causes of hepatocellular carcinoma and liver failure. However, the underlying molecular mechanism of hepatic steatosis and the progression to nonalcoholic steatohepatitis (NASH) are not fully understood. Herein, we discovered that AMPKα2 catalytic subunit showed reduced expression in the liver following high fat diet (HFD) feeding to mice. Importantly, knockout of AMPKα2 in mice aggravated NAFLD, hepatic steatosis, inflammation and fibrosis. On the other hand, hepatocyte-targeted overexpression of AMPKα2 prevented or reversed NAFLD indications. In vivo mechanistic studies revealed that increased phosphorylation of IKKα/β and NF-κB in HFD-fed AMPKα2-/- mice compared to WT mice, and treatment of these mouse cohorts with an inhibitor of NF-κB signaling for 4 weeks, effectively attenuated the progression of steatohepatitis and metabolic disorder features. In summary, AMPKα2 provides a protective role in the process of hepatic steatosis to NASH progression through suppression of liver NF-κB signaling.
Copyright © 2020 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  AMPK; Inflammation; NF-κB; Nonalcoholic fatty liver disease

Mesh:

Substances:

Year:  2020        PMID: 32502647     DOI: 10.1016/j.bbadis.2020.165854

Source DB:  PubMed          Journal:  Biochim Biophys Acta Mol Basis Dis        ISSN: 0925-4439            Impact factor:   5.187


  2 in total

1.  Ablation of Akt2 and AMPKα2 rescues high fat diet-induced obesity and hepatic steatosis through Parkin-mediated mitophagy.

Authors:  Shuyi Wang; Jun Tao; Huaguo Chen; Machender R Kandadi; Mingming Sun; Haixia Xu; Gary D Lopaschuk; Yan Lu; Junmeng Zheng; Hu Peng; Jun Ren
Journal:  Acta Pharm Sin B       Date:  2021-07-14       Impact factor: 11.413

2.  Targeting hepatic kisspeptin receptor ameliorates nonalcoholic fatty liver disease in a mouse model.

Authors:  Stephania Guzman; Magdalena Dragan; Hyokjoon Kwon; Vanessa de Oliveira; Shivani Rao; Vrushank Bhatt; Katarzyna M Kalemba; Ankit Shah; Vinod K Rustgi; He Wang; Paul R Bech; Ali Abbara; Chioma Izzi-Engbeaya; Pinelopi Manousou; Jessie Y Guo; Grace L Guo; Sally Radovick; Waljit S Dhillo; Fredric E Wondisford; Andy V Babwah; Moshmi Bhattacharya
Journal:  J Clin Invest       Date:  2022-05-16       Impact factor: 19.456

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.